In Vitro Susceptibility Testing Versus In Vivo Effectiveness

Medical Clinics of North America

Volumn 90, Issue 6, 2006, Pages 1077-1088

  Stratton, Charles W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLISTIN; DEXAMETHASONE; HEME; KETOLIDE; MACROLIDE; MENADIONE; METICILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; THIAMINE; VANCOMYCIN; VITAMIN K GROUP;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL STRAIN; CELLULAR IMMUNITY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SENSITIVITY; HOST; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NECROTIZING FASCIITIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 33751202419     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.07.003     Document Type: Review

References (55)

1. Fleming A. On the antibacterial action of cultures of a penicillium with special reference to their use in the isolation of B influenzae. Br J Exp Pathol 10 (1929) 226-236
2. Rodger K.C., Branch A., and Power E.E. Antibiotic therapy: correlation of clinical results with laboratory susceptibility tests. Can Med Assoc J 74 (1956) 605-612
3. Greenwood D. In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis 144 4 (1981) 380-385
4. Stratton C.W. Susceptibility testing revisited. In: Stafenini M., Gorstein F., and Fink L.M. (Eds). Progress in clinical pathology, vol IX (1983), Grune & Stratton, New York 65-100
5. Stratton C.W. Susceptibility testing today. Myth, reality, and new direction. Infect Control Hosp Epidemiol 9 6 (1988) 264-267
6. Stratton C.W. In vitro testing: correlations between bacterial susceptibility, body fluid levels and effectiveness of antibacterial therapy. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 3rd edition (1991), The Williams & Wilkins Company, Baltimore, MD 849-879
7. Weinstein L., and Dalton A.C. Host determinants of response to antimicrobial agents. N Engl J Med 279 9 (1968) 467-473
8. Weinstein L., and Dalton A.C. Host determinants of response to antimicrobial agents. N Engl J Med 279 10 (1968) 524-531
9. Weinstein L., and Dalton A.C. Host determinants of response to antimicrobial agents. N Engl J Med 279 11 (1968) 580-588
10. Clark R., and Rupper T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol 125 4 (2005) 629-637
11. Hargreaves D.C., and Medzhitov R. Innate sensors of microbial infections. J Clin Immunol 25 6 (2005) 503-510
12. Pancer Z., and Cooper M.D. The evolution of adaptive immunity. Annu Rev Immunol 24 (2006) 497-518
13. McCormick J.K., Yarwood J.M., and Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 55 (2001) 77-104
14. Faulkner L., Cooper A., Fantino C., et al. The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm. J Immunol 175 10 (2005) 6870-6877
15. Parsosnnet J., Hansmann M.A., Delaney M.L., et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to superantigen in menstruating women. J Clin Microbiol 43 9 (2005) 4628-4634
16. Norrby-Teglund A., Thulin P., Gan B.S., et al. Evidence for superantigen involvement in severe group A streptococcal tissue infections. J Infect Dis 184 7 (2001) 853-860
17. Norrby-Teglund A., Muller M.P., Mcgeer A., et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 37 3 (2005) 166-172
18. Tseng M.H., Wei B.H., Lin W.J., et al. Fatal sepsis and necrotizing pneumonia in a child due to community-acquired methicillin-resistant Staphylococcus aureus: case report and literature review. Scand J Infect Dis 37 6-7 (2005) 504-507
19. Kastenbauer S. Pneumococcal meningitis: a 21st century perspective. Lancet Neurol 5 2 (2006) 104-105
20. Weisfelt M., van de Beek D., Spanjaar L., et al. Clinical features, complications, and outcome in adults with peumococcal meningitis: a prospective case series. Lancet Neruol 5 2 (2006) 123-129
21. John C.C. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 18 2 (1994) 188-193
22. Koedel U., and Pfister H.W. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci Lett 225 1 (1997) 33-36
23. Stratton C.W., Aldridge K.E., and Gelfand M.S. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn Microbiol Infect Dis 22 2 (1995) 35-42
24. Proctor R.A., and Peters G. Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. Clin Infect Dis 27 3 (1998) 419-422
25. Baumert N., von Eiff C., Schaaff F., et al. Physiologic and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb Drug Resist 8 4 (2002) 253-260
26. Kipp F., Becker K., Peters G., et al. Evaluation of different methods to detect methicillin resistance in small-colony variants of Staphylococcus aureus. J Clin Microbiol 42 3 (2004) 1277-1279
27. Proctor R.A., Kahl B., von Eiff C., et al. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis 27 Suppl 1 (1998) S68-S74
28. Finch R.G. Introduction: standards of antibacterial performance. Clin Microbiol Infect 10 Suppl 2 (2004) S1-S5
29. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, gycopeptides, and linezolid. Infect Dis Clin North Am 17 (2003) 479-501
30. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of "bug and drug.". Nat Rev Microbiol 2 4 (2004) 289-300
31. McKinnon P.S., and Davis S.L. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis 23 4 (2004) 271-288
32. Jacobs M.R. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 7 11 (2001) 589-596
33. Schentag J.J., Gilliland K.K., and Paladino J.A. What have we learned from pharmacokinetic pharmacodynamic theories?. Clin Infect Dis 32 Suppl 1 (2001) S39-S46
34. Barger A., Fuhst C., and Wiedemann B. Pharmacologic indices in antibiotic therapy. J Antimicrob Chemother 52 6 (2003) 893-898
35. Mouton J.W. Breakpoints: current practice and future perspectives. Int J Antimicrob Agents 19 4 (2002) 323-331
36. Mouton J.W. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 17 3 (2003) 579-598
37. Mouton J.W., Dudley M.N., Cars O., et al. Standardization of pharmakinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 19 4 (2002) 355-358
38. Mouton J.W., Dudley M.N., Cars O., et al. Standardization of pharmakinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. Int J Antimicrob Agents 55 5 (2005) 601-607
39. Jacobs M.R. How can we predict bacterial eradication?. Int J Infect Dis 7 Suppl 1 (2003) S13-S20
40. Tenover F.C. Development and spread of bacterial resistance to antimicrobial agents: and overview. Clin Infect Dis 33 Suppl 3 (2001) S108-S115
41. Turnidge J.D., Ferraro M.J., and Jorgensen J.H. Susceptibility test methods: general considerations. In: Murray P.R., Baron E.J., Jorgensen J.H., et al. (Eds). Manual of clinical microbiology. 8th edition (2003), ASM Press, Washington, DC 1102-1107
42. Hubert S.K., Mohammed J.M., Fridkin S.K., et al. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected US hospitals. J Clin Microbiol 37 11 (1999) 3590-3593
43. Endtz H.P., Van Den Braak N., Ban Belkum A., et al. Comparison of eight methods to detect vancomycin resistance in enterococci. J Clin Microbiol 36 2 (1998) 592-594
44. Price C.S., Paule S., Noskin G.A., et al. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 37 7 (2003) 921-928
45. Decker M.D., Gregory D.W., Boldt J., et al. The detection of penicillin-resistant pneumococci. The compliance of hospital laboratories with recommended methods. Am J Clin Pathol 84 3 (1985) 357-360
46. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th informational supplement. CLSI document M100-S16 (2006), Clinical and Laboratory Standards Institute, Wayne, PA
47. Tan T.Q., Schutze G.E., Mason Jr. E.O., et al. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 38 5 (1994) 918-923
48. Empey P.E., Jennings H.R., Thornton A.C., et al. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 35 6 (2001) 687-690
49. Dylewski J., and Davidson R. Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis 25 1 (2006) 39-42
50. Peterson L.R. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?. Clin Infect Dis 42 2 (2006) 224-233
51. Dunne Jr. W.M., and Hardin D.J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp, Citrobacter spp, and Serratia spp. J Clin Microbiol 43 12 (2005) 5945-5949
52. Paterson D.L., and Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 4 (2005) 657-686
53. Siberry G.K., Tekle T., Carroll K., et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37 9 (2003) 1257-1260
54. Stein A., and Raoult D. Colistin: an antimicrobial for the 21st century. Clin Infect Dis 35 7 (2002) 901-902
55. Jones R.N., Anderegg T.R., and Swenson J.M. Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol 43 2 (2005) 925-927